All News
Filter News
Found 4,562 articles
-
Press Release: Continued strong growth in Q3 with key regulatory milestones achieved
10/28/2022
Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.
-
Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline
10/27/2022
Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced appointments to the company’s leadership team to support the continued advancement of its pipeline, including its clinical-stage programs, KAN-101 and ANK-700.
-
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
10/27/2022
CANbridge Pharmaceuticals Inc. announced that the company’s partner Mirum Pharmaceuticals, Inc. reported positive topline data from its Phase 3 MARCH study evaluating the safety and efficacy of LIVMARLI® oral solution in patients with progressive familial intrahepatic cholestasis.
-
Accelerating R&D Innovation, Sustainability and Production Capacity for 2030 – Expansion of Asahi Kasei Bioprocess America Facilities by Mid-2023
10/26/2022
Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, is currently undergoing a dramatic expansion of their Glenview, Illinois facilities to fuel innovation and to meet growing market needs for fluid management equipment, virus filtration and hollow fiber membrane technology.
-
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
10/26/2022
BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2022.
-
Recombinant Proteins Market Size to Hit Around USD 5.33 BN by 2030
10/26/2022
According to Latest Report Study, the global recombinant proteins market size is projected to hit around USD 5.33 billion by 2030 and growing at a CAGR of 12.82% from 2022 to 2030
-
Editas is reportedly in "advanced discussions" regarding the sale of its preclinical cancer lineup. The company told BioSpace it has undertaken a strategic review to inform opportunities.
-
Bay Area Biotech Companies Hiring Now
10/19/2022
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here's a look at a few of the bay area biotech companies hiring now. -
AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs
10/19/2022
AnHeart Therapeutics today announced the appointments of Heinrich Farin, M.D. as Senior Medical Director, Clinical Research and Michael J. Humphries, Ph.D., as VP, Head of US Medical Affairs.
-
As part of its third-quarter report, Roche announced it has cut two Phase II programs, one for hepatitis B and the other for geographic atrophy, a form of eye disease.
-
FDA Review: Phanes, Pfizer, GSK and More
10/14/2022
The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions. -
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences - October 13, 2022
10/13/2022
CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it will take part in two upcoming investor conferences.
-
CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress
10/13/2022
CANbridge Pharmaceuticals Inc. (HKEX:1228) announced that data from its gene therapy research agreement with the Horae Gene Therapy Center, at the UMass Chan Medical School, was presented at the 29th European Society of Gene and Cell Therapy Annual Congress in Edinburgh, Scotland, today.
-
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
10/12/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's resubmission of the Biologics License Application (BLA) for its investigational AAV gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A.
-
TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors
10/11/2022
TeraImmune, Inc., a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence the Company's Phase 1/2a clinical trial to evaluate its lead candidate, TI-168, in congenital Hemophilia A (HA) patients with refractory inhibitors.
-
BioMarin Pharmaceuticals announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.
-
Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
10/6/2022
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes™ trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT).
-
Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023Quarterly revenue expected to exceed US$27.0 million for quarter ended September 30, 2022, an all-time record
10/6/2022
Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s fiscal Q2 2023).
-
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 05, 2022
10/5/2022
Freeline Therapeutics Holdings plc announced that on September 30, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 416,850 of the Company’s ordinary shares.
-
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
10/4/2022
Freeline Therapeutics Holdings plc announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads to progressive organ damage and can result in early death as a result of a harmful build-up of fat in cells due to an enzyme deficiency.